Astragaloside IV Reduces Intestinal Inflammation by Blocking NLRP3 Activation

Jenn Hoskins
20th May, 2024

Astragaloside IV Reduces Intestinal Inflammation by Blocking NLRP3 Activation

Image Source: Natural Science News, 2024

Key Findings

  • Researchers at Hunan University of Chinese Medicine found that Astragaloside IV (AS-IV) can reduce inflammation in the small intestine caused by NSAIDs in rats
  • AS-IV significantly decreased the ulcer index and improved the surface and microstructure of the small intestinal mucosa
  • AS-IV also reduced levels of key inflammatory proteins and factors, suggesting it could be a promising treatment for NSAID-induced intestinal issues
Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain relief and inflammation reduction but can cause significant gastrointestinal issues, including inflammation and ulcers in the small intestine[2]. This can lead to serious complications such as bleeding and perforation[3]. While proton pump inhibitors (PPIs) are effective in preventing upper gastrointestinal bleeding, they do not protect the lower gastrointestinal tract and may even increase the risk of lower gastrointestinal bleeding[3]. Misoprostol has been shown to promote healing of small bowel ulcers in aspirin users, but its protection is limited[4]. A recent study conducted by Hunan University of Chinese Medicine investigated the potential of Astragaloside IV (AS-IV), a compound derived from the dried root of Astragalus membranaceus, to mitigate NSAID-induced inflammation in the small intestine[1]. The study focused on the effects of AS-IV on indomethacin (IND)-induced inflammation in the small intestine of rats. Researchers used various techniques such as hematoxylin-eosin (H&E) staining, electron microscopy, immunofluorescence, and ELISA tests to observe the surface morphology, ultrastructure, and molecular changes in the small intestinal mucosa. The results revealed that AS-IV significantly decreased the ulcer index, improved the surface morphology and microstructure of the small intestinal mucosa, and increased mucosal blood flow. These findings suggest that AS-IV could be a promising therapy for NSAID-induced intestinal inflammation. The study delved into the molecular mechanisms underlying the protective effects of AS-IV. Molecular docking revealed that AS-IV had a strong and stable binding capacity to proteins involved in inflammation, such as NLRP3, ASC, caspase-1, and NF-κB. Further experimental validation showed that AS-IV markedly decreased levels of inflammatory factors IL-1β and IL-18 and inhibited the protein expression of NLRP3, ASC, caspase-1, and NF-κB. These proteins and inflammatory factors are known to play crucial roles in the development of intestinal inflammation and ulcers. The findings from this study build on previous research that highlighted the limitations of current treatments for NSAID-induced gastrointestinal issues. For instance, while COX-2 inhibitors and PPIs can reduce upper gastrointestinal complications, they do not adequately protect the lower gastrointestinal tract and may even exacerbate small bowel injury[2][3]. The discovery that AS-IV can inhibit the activation of the NLRP3 inflammasome and reduce the release of IL-1β and IL-18 offers a new avenue for preventing and treating NSAID-induced small intestinal inflammation. In summary, the study conducted by Hunan University of Chinese Medicine provides compelling evidence that AS-IV can ameliorate IND-induced intestinal inflammation in rats by targeting key inflammatory pathways. This research not only expands our understanding of the potential therapeutic uses of AS-IV but also addresses the urgent need for effective treatments for NSAID-induced gastrointestinal complications.

MedicineHealthBiochem

References

Main Study

1) Astragaloside IV ameliorates indomethacin-induced intestinal inflammation in rats through inhibiting the activation of NLRP3 inflammasome.

Published 18th May, 2024

https://doi.org/10.1016/j.intimp.2024.112281

Related Studies

2) Non-steroidal anti-inflammatory drugs and the gastrointestinal tract.

https://doi.org/10.7861/clinmed.2021-0039

3) Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits.

https://doi.org/10.3748/wjg.v22.i48.10477

4) Misoprostol Heals Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding.

https://doi.org/10.1053/j.gastro.2018.06.056


Related Articles

An unhandled error has occurred. Reload 🗙